ArticleDiabetologia2025
Steatotic liver disease interacts with a polygenic risk score for triglyceride clearance to impact the risk of hypertriglyceridaemia: The Maastricht Study.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe pathogenesis of hypertriglyceridaemia is explained by a complex interplay between genetic and environmental factors. We hypothesised that intrahepatic lipid (IHL) content, which drives the production of triacylglycerol-rich VLDL particles, interacts with a polygenic risk score (PRS) for triglyceride clearance to impact the risk of hypertriglyceridaemia.
methodsWe used data from The Maastricht Study, a population-based prospective cohort study (n=3810; age: 60 years, 48% women, 10% hypertriglyceridaemia, 26% steatotic liver disease). We performed multivariable linear regression analyses to assess the impact of the cross-sectional interaction between IHL content (quantified by MRI) and a PRS for triglyceride clearance (based on nine SNPs) on fasting serum triglycerides, after adjustment for sociodemographic, lifestyle and cardiovascular risk factors. We subsequently explored whether a similar longitudinal interaction affects incident CVD during a 10 year follow-up.
resultsThere was an impact of interaction between IHL content and the PRS for triglyceride clearance on serum triglycerides (p=0.005). The strength of the association between a high PRS and risk of hypertriglyceridaemia was larger in individuals with steatotic liver disease (OR 6.196; 95% CI 3.966, 9.768) than in those without (OR 1.618; 95% CI 1.110, 2.380). A similar trend was observed for incident CVD risk (p=0.078). CONCLUSIONS/
interpretationGenetically predisposed individuals have a substantially higher risk of hypertriglyceridaemia when they also have steatotic liver disease. This gene-environment interaction might contribute to more personalised treatment approaches, which require further exploration in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.